TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17989310

Group type: COMPARATOR
Intervention: Normal glycemia
Number of subjects: 5842

Group type: COMPARATOR
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 5842

Group type: COMPARATOR
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 5842

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 5842

Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemia
Number of subjects: 5842

Group type: EXPERIMENTAL
Intervention: Log fasting plasma glucose
Number of subjects: 5842

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 5842

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 5842

Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 5842

Group type: EXPERIMENTAL
Intervention: Family history of diabetes
Number of subjects: 5842

Group type: EXPERIMENTAL
Intervention: Low education level
Number of subjects: 5842

Group type: EXPERIMENTAL
Intervention: A1C
Number of subjects: 5842
Study: 18721011

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel laparoscopic cholecystectomy (HS group=60 patients)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clip and cautery laparoscopic cholecystectomy (C&C group=60 patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel laparoscopic cholecystectomy (HS group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clip and cautery laparoscopic cholecystectomy (C&C group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 15580967

Group type: EXPERIMENTAL
Intervention: Opegan (Santen Pharmaceuticals, Osaka, Japan)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Soft-shell technique using Viscoat (Alcon Surgical, Fort Worth, TX)
Number of subjects: 69
Study: 11336102

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 9228196

Group type: EXPERIMENTAL
Intervention: Atropine (15 microg/kg i.v. loading dose followed by 0.15 microg/kg/min by i.v. infusion) with Noradrenaline (5 incremental doses of 10‐120 ng/kg/min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atropine (15 microg/kg i.v. loading dose followed by 0.15 microg/kg/min by i.v. infusion) with Tyramine (4 incremental doses of 5‐20 microg/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Noradrenaline (5 incremental doses of 10‐120 ng/kg/min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tyramine (4 incremental doses of 5‐20 microg/kg/min)
Number of subjects: 6
Study: 7962379

Group type: EXPERIMENTAL
Intervention: Buserelin, 500 micrograms subcutaneously daily, with variable amounts of menopausal gonadotrophins for ovarian stimulation.
Number of subjects: 11
Study: 2886561

Group type: EXPERIMENTAL
Intervention: Diuretics alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus SR oxprenolol
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Atenolol alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Timolol alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Acebutolol followed by atenolol
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (normal mass pretreatment)
Number of subjects: 78
Study: 31558426

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (n=42)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard care (n=45)
Number of subjects: 87
Study: 30498184

Group type: EXPERIMENTAL
Intervention: WhatsApp usage for dentistry-related purposes
Number of subjects: 105
Study: 26196527

Group type: EXPERIMENTAL
Intervention: Educational anaesthetic video (8 minutes)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard verbal briefing on anaesthesia (8 minutes)
Number of subjects: 100
Study: 25197669

Group type: EXPERIMENTAL
Intervention: 150 IU r-LH for 4 days followed by 400 IU r-FSH after downregulation with daily GnRh agonist
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional cycles (historical control)
Number of subjects: 43
Study: 22803101

Group type: EXPERIMENTAL
Intervention: Monotherapy with mesalazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with mesalazine and dalargin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference group (patients with irritable bowel syndrome)
Number of subjects: 0
Study: 19565392

Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Treatment (LSVT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional dysarthria therapy
Number of subjects: 10
Study: 17958845

Group type: EXPERIMENTAL
Intervention: Narrow-band UVB (NBUVB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Psoralen and ultraviolet A (PUVA)
Number of subjects: 50
Study: 16307694

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg at week 0 and week 2, followed by either placebo or infliximab (5 or 10 mg/kg) every 8 weeks or episodically on loss of response.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab treatment (5 or 10 mg/kg)
Number of subjects: 0
Study: 12004211

Group type: EXPERIMENTAL
Intervention: Inulin (24 g daily for 3 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10460604

Group type: EXPERIMENTAL
Intervention: Treatment-related mortality during induction and first remission of AML
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Infection-related deaths
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Haemorrhage-related deaths
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Cardiac failure-related deaths
Number of subjects: 341
Study: 7637747

Group type: EXPERIMENTAL
Intervention: Incentive spirometry (10 maximal inspirations every 2 hours during the day and while awake at night until pain subsided)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nonspirometry (control group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Incentive spirometry (among patients with thoracic bone infarction)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nonspirometry (among patients with thoracic bone infarction)
Number of subjects: 29
Study: 2663953

Group type: EXPERIMENTAL
Intervention: Doppler examination
Number of subjects: 40

Group type: COMPARATOR
Intervention: Venography
Number of subjects: 40
Study: 1164639

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.05% ointment and cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.05% ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluocortolone 0.2%
Number of subjects: 0
Study: 30476460

Group type: EXPERIMENTAL
Intervention: 16.2 g (270 mg I/mL)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 16.0 g (320 mg I/mL)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: DECTA (both doses)
Number of subjects: 52
Study: 28528472

Group type: EXPERIMENTAL
Intervention: iPTH assay 6 hours after surgery
Number of subjects: 150

Group type: COMPARATOR
Intervention: Daily assay of serum calcium and phosphorus (Control)
Number of subjects: 150
Study: 26425050

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Desflurane anesthesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both propofol and desflurane anesthesia
Number of subjects: 40
Study: 23504925

Group type: EXPERIMENTAL
Intervention: Nutrition education combined with sessions of vigorous extracurricular physical activity (VEPA) for 7 weeks, consisting of 13 sessions.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (CG) with no intervention.
Number of subjects: 54
Study: 21315678

Group type: EXPERIMENTAL
Intervention: 12-month moderate-intensity physical activity (3 times per week at gym and 3 times per week on their own)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 96
Study: 19817885

Group type: EXPERIMENTAL
Intervention: 27 tablets of 10 mg rizatriptan ODT per month
Number of subjects: 197

Group type: COMPARATOR
Intervention: 9 tablets of 10 mg rizatriptan ODT per month
Number of subjects: 197
Study: 17766654

Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy for women with endocrine-responsive disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for postmenopausal women with endocrine nonresponsive early breast cancer
Number of subjects: 0
Study: 15001822

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 178 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bupropion (BUP) 150 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 50
Study: 15568531

Group type: COMPARATOR
Intervention: Club foot
Number of subjects: 0
Study: 11443512

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day plus psyllium mucilloid 6.0 g
Number of subjects: 60

Group type: COMPARATOR
Intervention: Orlistat 120 mg three times a day plus placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo plus orlistat 120 mg three times a day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Psyllium plus orlistat 120 mg three times a day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (A and B) with orlistat
Number of subjects: 60
Study: 9212009

Group type: EXPERIMENTAL
Intervention: PA radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DL radiotherapy
Number of subjects: 0
Study: 8231168

Group type: COMPARATOR
Intervention: HSV
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HSV with patch
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (subcutaneous infusion of pentagastrin and carbachol)
Number of subjects: 120
Study: 3306780

Group type: EXPERIMENTAL
Intervention: Calf lung surfactant extract (CLSE) 90 mg by intratracheal instillation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study: 29395119

Group type: EXPERIMENTAL
Intervention: Ranibizumab (RBZ) 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) monotherapy
Number of subjects: 87
Study: 27737311

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) combined with cognitive training (N-back and sequence learning tasks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham stimulation (device turned off after 60 seconds)
Number of subjects: 9
Study: 25711327

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) for self-assessment of overall current health
Number of subjects: 4631

Group type: EXPERIMENTAL
Intervention: Short-Form 12-Item Version 2 Health Survey (SF-12V2)
Number of subjects: 4631

Group type: EXPERIMENTAL
Intervention: Physical Health Component Summary (PCS)
Number of subjects: 4631

Group type: EXPERIMENTAL
Intervention: Mental Health Component Summary (MCS)
Number of subjects: 4631
Study: 23088936

Group type: EXPERIMENTAL
Intervention: Intravenous nifekalant (0.3mg/kg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: No intravenous nifekalant (no-AAD group)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study: 21406472

Group type: EXPERIMENTAL
Intervention: Lapatinib plus trastuzumab (L+T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent lapatinib (L)
Number of subjects: 0
Study: 19106583

Group type: EXPERIMENTAL
Intervention: S‐1 plus Lentinan (LNT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: S‐1 alone
Number of subjects: 150
Study: 16431307

Group type: EXPERIMENTAL
Intervention: Intensive medical treatment (biofeedback training and/or laxative treatment)
Number of subjects: 119
Study: 12717482

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study: 10848778

Group type: EXPERIMENTAL
Intervention: Serum levels of ICTP
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Serum levels of BAP
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: ICTP
Number of subjects: 313
Study: 8646485

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy and HSCT (specific regimens not detailed)
Number of subjects: 42
Study: 1334515

Group type: EXPERIMENTAL
Intervention: Zileuton (5-lipoxygenase inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6367812

Group type: EXPERIMENTAL
Intervention: Oxybuprocaine 0.4% eye drops, one drop instilled 10 and 5 minutes preoperatively
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo eye drops, one drop instilled 10 and 5 minutes preoperatively
Number of subjects: 68
Study: 30732707

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 274

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 274
Study: 28915871

Group type: EXPERIMENTAL
Intervention: Key feature arm (n = 30)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Systematic arm (n = 26)
Number of subjects: 56
Study: 26530749

Group type: EXPERIMENTAL
Intervention: Capecitabine-based chemoradiation
Number of subjects: 74

Group type: COMPARATOR
Intervention: Gemcitabine-based chemoradiation
Number of subjects: 74
Study: 24075485

Group type: EXPERIMENTAL
Intervention: Sivelestat (0.2 mg/kg per hour)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 13
Study: 21785082

Group type: EXPERIMENTAL
Intervention: Breast displacement
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Breast displacement plus lead shielding
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 19196290

Group type: EXPERIMENTAL
Intervention: Outreach placement (5-week block)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Hospital-based training
Number of subjects: 49
Study: 17223855

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg twice daily for 2 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Grapefruit juice 200 ml three times daily for 2 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15452189

Group type: EXPERIMENTAL
Intervention: Cognitive-existential group therapy (CEGT) with 20 sessions of weekly group therapy plus three relaxation classes (n = 154)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Control condition of three relaxation classes alone (n = 149)
Number of subjects: 303
Study: 12106752

Group type: EXPERIMENTAL
Intervention: Vitamin B(6) 50 mg plus placebo pill/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Vitamin C 500 mg plus placebo pill/day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Vitamin B(6) 50 mg plus vitamin C 500 mg/day
Number of subjects: 55

Group type: COMPARATOR
Intervention: 2 placebo pills/day (control)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: All participants (collapsed data)
Number of subjects: 55
Study: 10477777

Group type: EXPERIMENTAL
Intervention: 40 mg of enoxaparin
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: 20 mg of enoxaparin
Number of subjects: 1102
Study: 8529731

Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic cisplatin, methotrexate and vinblastine chemotherapy
Number of subjects: 69
Study: 2311149

Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg.kg‐1 (single dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.2 mg.kg‐1 followed by 0.8 mg.kg‐1 (divided doses)
Number of subjects: 20
Study: 367874

Group type: EXPERIMENTAL
Intervention: Glucagon (administered intramuscularly and intravenously)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: COMPARATOR
Intervention: Anticholinergic drugs
Number of subjects: 9
Study: 6832198

Group type: EXPERIMENTAL
Intervention: Alinidine (0.5 mg/kg i.v.)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Propranolol (0.1 mg/kg i.v.)
Number of subjects: 2
Study: 31766467

Group type: EXPERIMENTAL
Intervention: Adaptive support ventilation (ASV)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pressure-control ventilation (PCV)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Volume-control ventilation (VCV)
Number of subjects: 15
Study: 29750027

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol
Number of subjects: 184

Group type: COMPARATOR
Intervention: tiotropium
Number of subjects: 184
Study: 26324738

Group type: EXPERIMENTAL
Intervention: Cixutumumab 10 mg/kg and the same antiestrogen (arm A)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cixutumumab alone (arm B)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cixutumumab (10 mg/kg) with or without antiestrogen
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Lower IR-A, IR-B, and total IR mRNA expression in tumor tissue (regardless of treatment)
Number of subjects: 93
Study: 23963691

Group type: EXPERIMENTAL
Intervention: Nasojejunal tube (NJT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Jejunostomy tube (JT)
Number of subjects: 68
Study: 22960612

Group type: EXPERIMENTAL
Intervention: d‐cycloserine 50mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (0mg d‐cycloserine)
Number of subjects: 27
Study: 19912599

Group type: EXPERIMENTAL
Intervention: 12+12 weeks of varenicline
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12 weeks of varenicline
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12 weeks of bupropion
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12 weeks of placebo
Number of subjects: 0
Study: 18829901

Group type: EXPERIMENTAL
Intervention: Bioresorbable calcium phosphate cement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Autogenous iliac bone graft
Number of subjects: 120
Study: 15636257

Group type: EXPERIMENTAL
Intervention: Primary Sjögren syndrome (PS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Secondary Sjögren syndrome (SS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 60
Study: 11244227

Group type: EXPERIMENTAL
Intervention: Calcipotriol cream (Daivonex/Dovonex) used daily combined with UVB treatments twice weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emollient used daily combined with UVB treatments three times weekly
Number of subjects: 0
Study: 9420370

Group type: EXPERIMENTAL
Intervention: Presence of a companion animal (dog)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No companion animal (control)
Number of subjects: 23
Study: 8123271

Group type: EXPERIMENTAL
Intervention: Heated breathing tubes at 30 degrees C (Group 2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Heated breathing tubes at 36 degrees C (Group 3)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Unheated breathing tubes (Group 1)
Number of subjects: 26
Study: 3333530

Group type: EXPERIMENTAL
Intervention: Dietary fat intake modification (reduced from 39% to 24% of energy, increased P/S ratio from 0.2 to 0.4-1.2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (baseline period)
Number of subjects: 0
Study: 29346916

Group type: EXPERIMENTAL
Intervention: Simplicial configuration model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized counterparts
Number of subjects: 0
Study: 26578718

Group type: EXPERIMENTAL
Intervention: Patellar tendon (PT) graft
Number of subjects: 65

Group type: COMPARATOR
Intervention: Hamstring tendon (HS) graft
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both PT and HS grafts
Number of subjects: 65
Study: 25216348

Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopy (LRA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional laparoscopy (TL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both LRA and TL
Number of subjects: 12
Study: 22014603

Group type: EXPERIMENTAL
Intervention: Variable dosing of intravitreal bevacizumab (1.25 mg/0.05 mL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fixed-interval dosing of intravitreal bevacizumab (every 4 to 6 weeks)
Number of subjects: 120
Study: 20577706

Group type: EXPERIMENTAL
Intervention: Topical lidocaine patches (LP) as an add-on to established pain medication
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Topical lidocaine patches (LP)
Number of subjects: 87
Study: 17498072

Group type: EXPERIMENTAL
Intervention: Sequential therapy with rFVIIa and APCC
Number of subjects: 4
Study: 15718407

Group type: EXPERIMENTAL
Intervention: COPD diaphragms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diaphragms
Number of subjects: 20
Study: 11756906

Group type: EXPERIMENTAL
Intervention: Normal saline solution injection (1‐2 mL boluses; mean volume 30 mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bipolar electrocoagulation (20 W, 10‐sec applications; mean time 100 sec)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Normal saline solution injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bipolar electrocoagulation
Number of subjects: 100
Study: 10923432

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 7979927

Group type: EXPERIMENTAL
Intervention: Physical training (progressive interval training with bicycle exercises, heel lifts, and step-climbing, performed twice weekly for 45 minutes over 3 months)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 24
Study: 3381069

Group type: COMPARATOR
Intervention: Conventional proctectomy and Brooke ileostomy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Mucosal proctectomy with ileoanal anastomosis (IAA)
Number of subjects: 54
Study: 30673864

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (1.25% NAC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.2% CHX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28927673

Group type: EXPERIMENTAL
Intervention: Prednisolone (40 to 60 mg/day for 14 days)
Number of subjects: 97

Group type: COMPARATOR
Intervention: ACTH (40 to 60 IU every other day for 14 days)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 97
Study: 25909526

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-based mouthrinse (Peridex)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Enzymatic-based mouthrinse (Biotène)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sterile water (negative control)
Number of subjects: 23